drugset

drugset / Trial / NCT02375958

PCA062 in pCAD-positive Tumors.

NCT02375958 ↗

Phase 1 Completed 47 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.

Timeline

Start: 2015-04-15
Primary completion: 2018-07-17
Completion: 2018-07-17

Publications

Duca M, Lim DW, Subbiah V, Takahashi S, Sarantopoulos J, Varga A, D'Alessio JA, Abrams T, Sheng Q, Tan EY, Rosa MS, Gonzalez-Maffe J, Sand-Dejmek J, Fabre C, Martin M. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. Mol Cancer Ther. 2022 Apr 1;21(4):625-634. doi: 10.1158/1535-7163.MCT-21-0652.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PCA062	Unknown	0.4 mg/kg	Intravenous
Subject	PCA062	Unknown	3.6 mg/kg	Intravenous
Subject	PCA062	Unknown	5 mg/kg	Intravenous

Indications